Pharmaceutical micronization specialist Micron Technologies has been acquired by private equity firm Arlington Capital Partners. Micron, which is based in Malvern, PA and has a facility in Dartford, UK, provides micronization services for both development and commercial production of drugs, including inhaled drugs, as well as analytical services.
Arlington Capital Partner Matthew Altman said that the company will expand: “Micron Technologies’ ability to provide leading bio-availability solutions across the drug development spectrum, from clinical phases to the commercial market, positions the company as a trusted long-term partner with its pharmaceutical clients for their most demanding drug development needs. We are enthusiastic about building upon the company’s leadership position and eager to continue to support the company as it enhances and expands its global particle size engineering and analytical service offerings.”
Read the Micron Technologies press release.
